During the past 10 years, mortality rates after cancer surgery have improved by 0.12%–0.14%, depending on race, researchers reported in study findings published in JAMA Network Open. However, the gap between outcomes for Black and White patients remains, they found.

Since the World Health Organization declared it a pandemic on March 11, 2020, the COVID-19 coronavirus—the greatest global public health emergency in a century—has disrupted or delayed many aspects of life, including cancer care. But it’s also opened new opportunities for nursing innovation and brought much-needed change to health care. Here’s where we are one year later.

On February 12, 2021, the U.S. Food and Drug Administration (FDA) approved trilaciclib (Cosela™) as the first therapy in its class to reduce the frequency of chemotherapy-induced myelosuppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer. Trilaciclib inhibits cyclin-dependent kinase 4/6 (CDK 4/6) enzymes to prevent bone marrow damage.   

Marianne, an oncology nurse navigator, is preparing a cancer treatment summary and survivorship care plan for Sylvia, who finished breast cancer treatment six weeks ago. Sylvia was treated with neoadjuvant therapy followed by mastectomy, reconstruction, and radiation. Her tumor was characterized as multifocal invasive ductal carcinoma, grade 2, estrogen and progesterone positive, and HER2/neu negative. Sylvia has no family history of breast cancer. Marianne notices that the oncologist recorded Sylvia’s cancer as a stage IB.

When they launched in 2020, oncology nurses recognized the first five ONS Guidelines™ for cancer treatment-related symptoms and adverse events as the evidence-based standard for patient care. Now, the ECRI Guidelines Trust, a national evaluation organization, has given them that distinction as well, including all of ONS’s current guidelines in its repository.

When ONS Past President Mary Gullatte, PhD, RN, ANP-BC, AOCN^®, LSSYB, FAAN, was elected by her peers in 2012, she said it was the “absolute pinnacle of my oncology nursing career”: Gullatte made the ONS history books as the Society’s first African American president.

Pandemics have a tremendous impact on societies and individuals alike. From incidence rates to death tolls, financial hardship to job loss, and anxiety to isolation, we’ve all been affected in one way or another—although some much more than others.

A nurse was the first U.S. citizen to receive the COVID-19 coronavirus vaccine. Biden also recently appointed a nurse to the COVID-19 advisory board. Clearly the country recognizes nurses’ consistent power and trustworthiness, and nurses can use that power to educate the public about the Biden administration’s tactics to get vaccines to the rest of the country and control the spread.

On February 9, 2021, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo^®) for use in patients with locally advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate. FDA also granted accelerated approval to cemiplimab-rwlc for patients with metastatic BCC previously treated with an HHI or for whom an HHI is not appropriate. 

Palliative radiation targeted directly to the tumor with stereotactic body radiation therapy eliminated metastatic pain in 33% of patients for six months compared to 16% with standard radiation therapy. Researchers reported the study findings at the American Society for Radiation Oncology annual meeting.